These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12788837)

  • 1. The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes.
    Dandona P; Aljada A; Chaudhuri A; Bandyopadhyay A
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2422-9. PubMed ID: 12788837
    [No Abstract]   [Full Text] [Related]  

  • 2. [Insulin resistance and atherosclerosis. Controlling diabetes on 2 fronts].
    MMW Fortschr Med; 2003 Sep; 145(37):65. PubMed ID: 14584452
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin].
    Tamura H; Mokuno H; Daita H
    Nihon Rinsho; 2006 Nov; 64(11):2119-25. PubMed ID: 17087306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes.
    Eckel RH; Wassef M; Chait A; Sobel B; Barrett E; King G; Lopes-Virella M; Reusch J; Ruderman N; Steiner G; Vlassara H
    Circulation; 2002 May; 105(18):e138-43. PubMed ID: 11994264
    [No Abstract]   [Full Text] [Related]  

  • 6. Manipulating the vascular biology of coronary atherosclerosis in diabetes: new opportunities.
    Orford JL; Kinlay S; Fernandes J; Behrendt D; Ganz P; Selwyn AP
    J Lab Clin Med; 2001 Feb; 137(2):82-92. PubMed ID: 11174464
    [No Abstract]   [Full Text] [Related]  

  • 7. [Disorders of the cardiovascular system in patients with diabetes mellitus].
    Kliachko VR; Mazovetskiĭ AG; Slavina LS
    Kardiologiia; 1974 Oct; 14(10):150-8. PubMed ID: 4280467
    [No Abstract]   [Full Text] [Related]  

  • 8. Endothelial dysfunction, inflammation and diabetes.
    Dandona P; Aljada A; Chaudhuri A; Mohanty P
    Rev Endocr Metab Disord; 2004 Aug; 5(3):189-97. PubMed ID: 15211090
    [No Abstract]   [Full Text] [Related]  

  • 9. Rosiglitazone: potential beneficial impact on cardiovascular disease.
    Viberti GC
    Int J Clin Pract; 2003 Mar; 57(2):128-34. PubMed ID: 12661797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the endothelium to prevent diabetes-related atherosclerosis.
    Kearney MT
    Diab Vasc Dis Res; 2010 Jul; 7(3):177. PubMed ID: 20699387
    [No Abstract]   [Full Text] [Related]  

  • 11. [Atherogenic risk in diabetes: study of arteriosclerotic complications and their relationship with prolonged hypoglycemic treatment].
    Baraldi B; Cristini PD; Maestri G; Maj F; Cocuzza E; Angeli G
    Clin Ter; 1978 Jul; 86(1):37-53. PubMed ID: 743852
    [No Abstract]   [Full Text] [Related]  

  • 12. Beneficial effects of insulin on endothelial function, inflammation, and atherogenesis and their implications.
    Kuritzky L; Nelson SE
    J Fam Pract; 2005 Jun; 54(6):S7-9. PubMed ID: 16021783
    [No Abstract]   [Full Text] [Related]  

  • 13. Current concepts and controversies in the pathogenesis, prevention, and treatment of the macrovascular complications of diabetes.
    Mazzone T
    J Lab Clin Med; 2000 Jun; 135(6):437-43. PubMed ID: 10850642
    [No Abstract]   [Full Text] [Related]  

  • 14. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 15. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis.
    Dandona P; Aljada A
    Am J Cardiol; 2002 Sep; 90(5A):27G-33G. PubMed ID: 12231076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets.
    Plutzky J; Viberti G; Haffner S
    J Diabetes Complications; 2002; 16(6):401-15. PubMed ID: 12477625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Timely intervention with insulin sensitizer. Controlling cardiovascular risks].
    MMW Fortschr Med; 2003 Jun; 145(23):56-7. PubMed ID: 12854228
    [No Abstract]   [Full Text] [Related]  

  • 18. [What should be the target of therapy in the adult-onset diabetes mellitus?].
    Yki-Järvinen H
    Duodecim; 1999; 115(10):1119-20. PubMed ID: 11877850
    [No Abstract]   [Full Text] [Related]  

  • 19. Hyperinsulinaemia as a possible risk factor of macrovascular disease in diabetes mellitus. An overview.
    Janka HU; Standl E
    Diabete Metab; 1987 Jul; 13(3 Pt 2):279-83. PubMed ID: 3308556
    [No Abstract]   [Full Text] [Related]  

  • 20. Type 2 diabetes and atherosclerosis.
    Donnelly R; Davis KR
    Diabetes Obes Metab; 2000 Mar; 2 Suppl 1():S21-30. PubMed ID: 11225756
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.